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INTRODUCTION 
The genetically diverse Orthocoronavirinae (coronavirus, 
CoV) family circulates in many avian and mammalian spe-
cies. Phylogenetically, CoVs are divided into 4 genera: alpha 
(group 1), beta (group 2), gamma (group 3) and delta (group 
4). Three new human CoV have emerged in the past 20 years 
with severe acute respiratory syndrome CoV (SARS-CoV) in 
2002, Middle East respiratory syndrome CoV (MERS-CoV) in 
2012, and now SARS-CoV-2 in 2019 (1-3). In fact, all human 
CoV are thought to have emerged originally as zoonoses (4-
6). The ongoing SARS-CoV-2 pandemic (referred to as 
COVID-19, Coronavirus disease 2019) has caused over 
500,000 infections and over 25,000 deaths in 199 countries. 
Like SARS- and MERS-CoV, the respiratory disease caused by 
SARS-CoV-2 can progress to acute lung injury (ALI), an end 
stage lung disease with limited treatment options and very 
poor prognoses(3, 7, 8). This emergence paradigm is not lim-
ited to humans. A novel group 1 CoV called swine acute diar-
rhea syndrome CoV (SADS-CoV) recently emerged from bats 
causing the loss of over 20,000 pigs in Guangdong Province, 
China (9). More alarmingly, many group 2 SARS-like and 
MERS-like coronaviruses are circulating in bat reservoir spe-
cies that can use human receptors and replicate efficiently in 
primary human lung cells without adaptation(9-12). The 
presence of these “pre-epidemic” zoonotic strains foreshadow 
the emergence and epidemic potential of additional SARS-
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Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most 
recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Herein, we show 
that the ribonucleoside analog β-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral 
activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well 
as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor 
remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic 
administration of EIDD-2801, an orally bioavailable NHC-prodrug (β-D-N4-hydroxycytidine-5′-isopropyl 
ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV 
yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host 
cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against 
multiple coronaviruses and oral bioavailability highlight its potential utility as an effective antiviral against 
SARS-CoV-2 and other future zoonotic coronaviruses. 
like and MERS-like viruses in the future. Given the diversity 
of CoV strains in zoonotic reservoirs and a penchant for 
emergence, broadly active antivirals are clearly needed for 
rapid response to new CoV outbreaks in humans and domes-
ticated animals. 
Currently, there are no approved therapies specific for any 
human CoV. β-D-N4-hydroxycytidine (NHC, EIDD-1931) is
orally bioavailable ribonucleoside analog with broad-spec-
trum antiviral activity against various unrelated RNA viruses 
including influenza, Ebola, CoV, and Venezuelan equine en-
cephalitis virus (VEEV)(13-16). For VEEV, the mechanism of 
action (MOA) for NHC has been shown to be through lethal 
mutagenesis where deleterious transition mutations accumu-
late in viral RNA(14, 17). Thus, we sought to determine NHC’s 
breadth of antiviral activity against multiple emerging CoV, 
its mechanism of action for CoV and its efficacy in mouse 
models of CoV pathogenesis. 
RESULTS 
NHC potently inhibits MERS-CoV and newly emerging 
SARS-CoV-2 replication 
To determine whether NHC blocks the replication of highly 
pathogenic human CoV, we performed antiviral assays in cell 
lines with MERS-CoV and the newly emerging SARS-CoV-2. 
We first assessed the antiviral activity of NHC against MERS-
CoV in the human lung epithelial cell line Calu-3 2B4 (“Calu3” 
cells). Using a recombinant MERS-CoV expressing nanolucif-
erase (MERS-nLUC)(18), we measured virus replication in 
cultures exposed to a dose range of drug for 48hr. NHC was 
potently antiviral with an average half-maximum effective 
concentration (IC50) of 0.15 μM and no observed cytoxicity in
similarly treated uninfected cultures across the dose range 
(50% cytotoxic concentration, CC50, >10 μM) (Fig. 1A). The
therapeutic index for NHC was >100. Using a clinical isolate 
of SARS-CoV2 (2019-nCoV/USA-WA1/2020), we performed 
antiviral assays in African green monkey kidney (Vero) cells 
and found NHC was potently antiviral with an IC50 of 0.3 μM
and CC50 of >10 μM (Fig. 1B). We then determined the antivi-
ral activity of NHC against SARS-CoV-2 in the Calu-3 cells 
through the measurement of infectious virus production and 
viral genomes. We observed a dose-dependent reduction in 
virus titers (Fig. 1C) with an IC50 of 0.08 μM. Viral genomic
RNA was quantitated in clarified supernatants by qRT-PCR 
(Fig. 1D). Like the effect on infectious titers, we found a dose-
dependent reduction in viral genomic RNA and a similar cal-
culated IC50 of 0.09 μM. Collectively, these data demonstrate
that NHC is potently antiviral against two genetically distinct 
emerging CoV. 
NHC is highly active against SARS-CoV-2, MERS-CoV, 
and SARS-CoV in primary human airway epithelial cell 
cultures 
To determine if NHC would be similarly antiviral in primary 
human cells, we performed a series of studies in primary air-
way epithelial (HAE) cell cultures. HAE model the architec-
ture and cellular complexity of the conducting airway and are 
readily infected by multiple human and zoonotic CoV, includ-
ing SARS- and MERS-CoV (19). We first assessed cytotoxicity 
of NHC in HAE treated with an extended dose range for 48hr 
using quantitative PCR of cell death-related gene transcripts 
as our metric. NHC treatment did not appreciably alter gene 
expression even at doses up to 100 μM (fig. S1). We then
sought to determine if NHC would inhibit clinical isolate 
SARS-CoV-2 replication in HAE. We observed a dose depend-
ent reduction in SARS-CoV-2 infectious virus production (Fig. 
2A). In MERS-CoV infected HAE, NHC substantially reduced 
virus production with maximal titer reduction of > 5 logs at 
10 μM (average IC50 = 0.024 μM), which correlated with re-
duced genomic (ORF1) and subgenomic (ORFN) RNA in 
paired samples (Fig. 2B). We observed similar trends in titer 
reduction (> 3 log at 10 μM, average IC50 = 0.14 μM) and in
copies of genomic and subgenomic RNA in SARS-CoV- in-
fected HAE (Fig. 2C). Thus, NHC was potently antiviral 
against SARS-CoV-2, MERS-CoV and SARS-CoV in primary 
human epithelial cell cultures without cytotoxicity. 
NHC is effective against remdesivir (RDV)-resistant vi-
rus and multiple distinct zoonotic CoV 
CoV are taxonomically divided into multiple genogroups (al-
pha, beta, gamma, delta) but human-infecting CoV are found 
in only the alpha and beta subgroups thus far (Fig. 3A). There 
is high sequence conservation in the RNA-dependent RNA 
polymerase (RdRp, nsp12) across CoV (Fig. 3A). For example, 
the RdRp of SARS-CoV-2 has 99.1% similarity and 96% amino 
acid identity to that of SARS-CoV (Fig. 3A). To gain insight 
into structural conservation of RdRp across the CoV family, 
we modeled the variation reflected in the RdRp dendrogram 
in Fig. 3A onto the structure of the SARS-CoV RdRp (20) (Fig. 
3B). The core of the RdRp molecule and main structural mo-
tifs that all RdRp harbor (Fig. 3B and fig. S2) are highly con-
served among CoV including SARS-CoV-2. We previously 
reported that CoV resistance to another broad spectrum nu-
cleoside analog, RDV, was mediated by RdRp residues F480L 
and V557L in a model coronavirus mouse hepatitis virus 
(MHV) and in SARS-CoV, resulting in a 5-fold shift in IC50 
(Fig. 3C)(21). Consequently, we tested whether RDV re-
sistance mutations in MHV conferred cross-resistance to 
NHC. In fact, the two RDV resistance mutations, alone or to-
gether, conferred increased sensitivity to inhibition by NHC 
(Fig. 3D). As our previous studies have demonstrated a high 
genetic barrier to NHC for VEEV, influenza and CoV (14-16), 
the lack of cross-resistance further suggests that NHC and 
RDV may select for exclusive and mutually sensitizing re-
sistance pathways. 
To explore the breadth of antiviral efficacy against zoono-
tic CoV, we performed antiviral assays in HAE with three 
zoonotic Bat-CoV: SHC014, HKU3, and HKU5. Closely related 
to the beta 2b SARS-CoV, Bat-CoV SHC014 is capable of rep-
licating in human cells without adaptation(11), suggesting its 
potential for zoonotic emergence into humans. The more dis-
tantly related SARS-like beta 2b CoV, recombinant Bat-CoV 
HKU3, has a modified receptor binding domain to facilitate 
growth in cell culture (22). Lastly, Bat-CoV HKU5 is a MERS-
like beta 2c CoV (23). NHC diminished infectious virus pro-
duction and the levels of genomic/subgenomic viral RNA in 
HAE in a dose-dependent manner for all three Bat-CoVs (Fig. 
4). Therefore, the antiviral activity of NHC was not limited by 
natural amino acid variation in the RdRp, which among the 
group 2b and group 2c CoV can vary by almost 20%. Moreo-
ver, these data suggest that if another SARS- or MERS-like 
virus were to spillover into humans in the future, they would 
likely be susceptible to the antiviral activity of NHC. 
NHC antiviral activity is associated with increased viral 
mutation rates 
It has recently been shown that NHC treatment increases the 
mutation rate in viral genomic RNA of RSV (24), VEEV (14), 
influenza (24), and our previous study used RNA seq to show 
that overall transition mutation frequency is increased dur-
ing NHC treatment of MHV and MERS-CoV during infection 
in continuous cell lines(16). We sought to determine if NHC 
would increase the mutation frequency during MERS-CoV in-
fection in human primary HAE. Using MERS-CoV-infected 
HAE treated with either vehicle or a dose range of NHC or 
RDV, we show that both drugs reduced virus titers in a dose-
dependent manner (Fig. 5A). We then used a highly-sensitive 
high-fidelity deep sequencing approach (Primer ID NGS), 
which uses barcoded degenerate primers and Illumina in-
dexed libraries to determine accurate mutation rates on viral 
RNA production (25). Using this approach, we analyzed a 538 
bp region of viral genomic RNA in nonstructural protein 15 
(nsp15). The error rates (#mutations/10,000 bases) in vehicle- 
(0.01) or RDV- (0.01) treated cultures were very low. RDV is 
reported to act via chain termination of nascent viral RNA, 
and thus the low error rates in RDV-treated cultures are in 
line with the proposed MOA (26). In contrast, the error rate 
was significantly increased in NHC-treated MERS-CoV RNA 
in a dose-dependent manner (Two-way ANOVA with Dun-
nett’s multiple comparison test; 10-fold increase at 10 μM, P
< 0.0001 at 24 and 48 hpi; 5-fold increase at 1μM, P < 0.0001
at 24 hpi and P = 0.0015 at 48 hpi) (Fig. 5C). The magnitude 
of the error rate in NHC-treated cultures correlated with vi-
rus titer reduction. At 48 hpi the respective error rate and 
virus titer was 0.015 and 3.96E+06 pfu/mL for vehicle treat-
ment, 0.045 and 2.86E+04 pfu/mL with 1 μM NHC; and 0.090
and 1.5E+02 pfu/mL 10 μM NHC. Thus, with 1 μM NHC a 3-
fold increase in error rate resulted in a 138-fold decrease in 
virus titer, while with 10 μM NHC a 6-fold increase in error
rate resulted in a 26,000-fold decrease in virus titer. 
We then examined the mutational spectra induced by 
NHC, which can be incorporated into viral RNA as a substi-
tution for either cytosine (C) or uracil (U). RNA-mutagenic 
antivirals may incorporate in both nascent negative and pos-
itive sense RNA during genome replication (Fig. 5D). Ade-
nine-to-guanine (A-to-G) and uracil-to-cytosine (U-to-C) 
transitions were enriched in MERS-CoV genomic RNA in an 
NHC dose-dependent manner (Fig. 5E). Collectively, these 
data used high-fidelity sequence analysis to demonstrate a 
specific enrichment for A:G and C:U transitions in MERS-
CoV RNA after NHC treatment of primary HAE cell cultures. 
Therapeutic EIDD-2801 reduces SARS-CoV replication 
and pathogenesis 
Given the promising antiviral activity of NHC in vitro, we 
next evaluated its in vivo efficacy using EIDD-2801, an orally 
bioavailable prodrug of NHC (β-D-N4-hydroxycytidine-5′-iso-
propyl ester), designed for improved in vivo pharmacokinet-
ics and oral bioavailability in humans and non-human 
primates (15). Importantly, the plasma profiles of NHC and 
EIDD-2801 are similar in mice following oral delivery (15). We 
first performed a prophylactic dose escalation study in 
C57BL/6 mice where we orally administered vehicle (10% 
PEG, 2.5% Cremophor RH40 in water) or 50, 150, or 500 
mg/kg EIDD-2801 2hr prior to intranasal infection with 
5E+04 PFU of mouse-adapted SARS-CoV (SARS-MA15), and 
then vehicle or drug every 12 hours thereafter. Beginning on 
3 days post-infection (dpi) and through the end of the study, 
body weight loss compared to vehicle treatment was signifi-
cantly diminished (50 mg/kg) or prevented (150, 500 mg/kg) 
with EIDD-2801 prophylaxis (Two-way ANOVA with Dun-
nett’s multiple comparison test, P < 0.0001) (fig. S3A). Lung 
hemorrhage was also significantly reduced 5 dpi with 500 
mg/kg EIDD-2801 treatment (Kruskal-Wallis Test, P = 0.010, 
fig. S3B). Interestingly, there was a dose-dependent reduction 
in SARS-CoV lung titer (median titers: 50 mg/kg = 7E+03 
pfu/mL, 150 mg/kg = 2.5E+03 pfu/mL, 500 mg/kg = 50 
pfu/mL, vehicle = 6.5E+04 pfu/mL) with significant differ-
ences (Kruskal-Wallis with Dunn’s multiple comparisons 
test) among the vehicle, 150 mg/kg (P = 0.03) and 500 mg/kg 
(P = 0.006) groups. Thus, prophylactic orally administered 
EIDD-2801 was robustly antiviral and able to prevent SARS-
CoV replication and disease. 
Since only the 500 mg/kg group significantly diminished 
weight loss, hemorrhage and reduced lung titer to near un-
detectable levels, we tested this dose under therapeutic treat-
ment conditions to determine if EIDD-2801 could improve 
the outcomes of an ongoing CoV infection. As a control, we 
initiated oral vehicle or EIDD-2801 2 hours prior to infection 
with 1E+04 pfu SARS-MA15. For therapeutic conditions, we 
initiated EIDD-2801 treatment 12, 24, or 48 hours after infec-
tion. After initiating treatment, dosing for all groups was per-
formed every 12 hours for the duration of the study. Both 
prophylactic treatment initiated 2 hours prior to infection 
and therapeutic treatment initiated 12 hours after infection 
significantly (Two-way ANOVA with Tukey’s multiple com-
parison test) prevented body weight loss following SARS-CoV 
infection on 2 dpi and thereafter (-2 hours: P = 0.0002 to 
<0.0001; +12 hours: P = 0.0289 to <0.0001) as compared to 
vehicle treated animals (Fig. 6A). Treatment initiated 24 hpi 
also significantly reduced body weight loss (3-5 dpi, P = 0.01 
to <0.0001) although not to the same degree as the earlier 
treatment initiation groups. When initiated 48 hpi, body 
weight loss was only different from vehicle on 4 dpi (P = 
0.037, Fig. 6A). Therapeutic EIDD-2801 significantly (Krus-
kal-Wallis with Dunnett’s multiple comparison test) reduced 
lung hemorrhage when initiated up to 24 hours after infec-
tion (-2, +12, and +24 hours P < 0.0001) mirroring the body 
weight loss phenotypes (Fig. 6B). Interestingly, all EIDD-2801 
treated mice had significantly (Kruskal-Wallis with Dunnett’s 
multiple comparison test) reduced viral loads in the lungs 
even in the +48 hours group (All P < 0.0001, Fig. 6C), which 
experienced the least protection from body weight loss and 
lung hemorrhage. We also measured pulmonary function via 
whole body plethysmography (WBP). In Fig. 6D, we show the 
WBP enhanced pause (PenH) metric, which is a surrogate 
marker for bronchoconstriction or pulmonary obstruction 
(27), was significantly (Two-way ANOVA with Dunnett’s mul-
tiple comparison test) improved throughout the course of the 
study if treatment was initiated up to 12 hours after infection 
(-2 hours: 2d pi to 5 dpi, P < 0.0001 to 0.019, +12 hours: 2 dpi 
to 5 dpi, P < 0.0001 to 0.0192) although the +24 hours group 
showed sporadic improvement as well (3 dpi P = 0.002) (Fig. 
6D). Lastly, we blindly evaluated hematoxylin and eosin-
stained lung tissue sections for histological features of ALI 
using two different and complementary scoring tools (18), 
which show that treatment initiated up to +12 hours signifi-
cantly reduced ALI (Kruskal-Wallis with Dunn’s multiple 
comparison test) (American Thoracic Society (ATS) Lung In-
jury Score: -2 hours P = 0.0004, +12 hours P = 0.0053, Diffuse 
alveolar damage (DAD) Score: -2 hours P = 0.0015, +12 hours 
P = 0.0004, Fig. 6E). Altogether, therapeutic EIDD-2801 was 
potently antiviral against SARS-CoV in vivo but the degree of 
clinical benefit was dependent on the time of initiation post-
infection. 
EIDD-2801 prophylactic and therapeutic efficacy corre-
lates with increased MERS-CoV mutation rate 
After obtaining promising in vivo efficacy data with SARS-
CoV, we investigated whether EIDD-2801 would be effective 
against MERS-CoV. As the murine ortholog of the MERS-CoV 
receptor, dipeptidyl peptidase 4 (DPP4), does not support vi-
ral binding and entry, all in vivo studies were performed in 
genetically modified mice encoding a murine DPP4 receptor 
encoding two human residues at positions 288 and 330 
(hDPP4 288/330 mice)(18, 28). Similar to our SARS-CoV data, 
all doses of prophylactic EIDD-2801 (50, 150 and 500 mg/kg) 
protected hDPP4 288/330 mice (fig. S4) from significant body 
weight loss (Two-way ANOVA with Dunnett’s multiple com-
parison test, P = 0.03 to < 0.0001), lung hemorrhage (Kruskal-
Wallis with Dunn’s multiple comparison test, P = 0.01 to 
<0.0001), and virus replication which was undetectable 
(Kruskal-Wallis with Dunn’s multiple comparison test, P < 
0.0001) regardless of drug dose following intranasal infection 
with 5E+04 PFU mouse-adapted MERS-CoV (fig. S4). 
We then evaluated the therapeutic efficacy EIDD-2801 fol-
lowing the promising results of our prophylactic studies. Sim-
ilar to our SARS-CoV study, EIDD-2801 treatment 
administered before or 12 hours after intranasal mouse-
adapted MERS-CoV infection (5E+04 PFU) prevented body 
weight loss from 2 through 6 dpi (Two-way ANOVA with 
Tukey’s multiple comparison test, Fig. 7A, P = 0.02 to 
<0.0001) and lung hemorrhage on 6 dpi (Kruskal-Wallis with 
Dunn’s multiple comparison test, P = 0.0004 to < 0.0001, Fig. 
7B), but treatment initiated 24 or 48 hours did not offer sim-
ilar protection. Unlike body weight loss and lung hemorrhage 
data which varied by treatment initiation time, virus lung ti-
ter on 6 dpi was significantly reduced to the limit of detection 
in all treatment groups (Kruskal-Wallis with Dunn’s multiple 
comparison test, Fig. 7C, P < 0.0001). Interestingly, when vi-
ral genomic RNA was quantified in paired samples of lung 
tissue, EIDD-2801 significantly reduced quantities of viral 
RNA (One-way ANOVA with Dunnett’s multiple comparison 
test, P <0.0001 to 0.017) in an initiation time-dependent man-
ner for all groups except for +48 hours (Fig. 7D). The discrep-
ancy among infectious titers and viral RNA suggests that 
accumulated mutations render the particles non-infectious 
and undetectable by plaque assay, consistent with the MOA. 
To gauge the effect of EIDD-2801 treatment on lung function, 
we assessed pulmonary function by WBP. Mirroring the body 
weight loss data, normal pulmonary function was only ob-
served in groups where treatment was initiated prior to or 12 
hours after infection (Two-way ANOVA with Tukey’s multiple 
comparison test, -2hr: P < 0.0001 3 dpi, P = 0.0002 4 dpi, 
+12hr: P < 0.0001 3 dpi, P = 0.0008 4 dpi, Fig. 7E). Collec-
tively, these data demonstrate that NHC prodrug, EIDD-2801,
robustly reduces MERS-CoV infectious titers, viral RNA, and
pathogenesis under both prophylactic and early therapeutic
conditions.
To study the molecular mechanisms associated with drug 
performance in vivo, we investigated the correlation between 
infectious virus production and EIDD-2801-mediated muta-
genesis of MERS-CoV RNA under therapeutic treatment con-
ditions. Using Primer ID NGS, we measured the mutation 
rates of both viral genomic RNA (non-structural protein 10, 
nsp10) and host interferon stimulated gene 15 (ISG15) mRNA, 
a highly up-regulated innate immune-related gene after 
MERS-CoV infection (Fig. 7F). Primer ID NGS measures the 
mutational frequency in single RNA molecules, each of which 
are represented by a single template consensus sequence 
(TCS) (25). Viral TCS were significantly reduced (Two-way 
ANOVA with Tukey’s multiple comparison test, -2 hours P 
<0.0001, +12 hours P = 0.0001, +24 hours P = 0.02) in a treat-
ment initiation time-dependent manner (Fig. 7G) similar to 
viral genomic RNA measured by qRT-PCR. In contrast, the 
numbers of ISG15 TCS were similar (P = 0.2 to 0.8) for all 
groups indicating that neither vehicle nor drug treatment sig-
nificantly affected the levels of or mutated ISG15 mRNA tran-
scripts (Fig. 7G). Similar to our TCS data in Fig. 6G, the total 
error rate in viral nsp10 was significantly increased (Two-way 
ANOVA with Tukey’s multiple comparison test) in groups 
where treatment was initiated prior to (-2 hours, median er-
ror rate = 10.5 errors/10,000 bases, P < 0.0001) and up to 24 
hours post infection (12 hours, median error rate = 8.2 er-
rors/10,000 bases, P < 0.0001 ; +24 hours, median error rate 
= 5.4 errors/10,000 bases, P = 0.0003) but the error rates in 
ISG15 remained at baseline for all groups (Fig. 7H). In addi-
tion, nucleotide transitions observed in MERS-CoV genomes 
in vitro, were also observed in vivo in groups where treatment 
was initiated prior to and up to 12 hours post infection (Two-
way ANOVA with Tukey’s multiple comparison test, P = 
0.0003 to < 0.0001) (Fig. 7I). Importantly, these transitions 
were not observed in host ISG15 mRNA (Fig. 7I). Lastly, the 
EIDD-2801 dose-dependent mutagenesis of viral RNA corre-
lated with an increase in codon change frequency, including 
stop codons, in mice where treatment was initiated 12 hours 
or before (Two-way ANOVA with Tukey’s multiple compari-
son test, vehicle median = 3.4; -2hr median = 22.8, P = 0.0035; 
+12 hours median = 20.0, P = 0.0004, Fig. 7J). Thus, approxi-
mately 20% of the mutations observed in the -2 hours and
+12 hours groups resulted in a codon change and alteration
of the nsp10 protein sequence. When extrapolating our re-
sults from nsp10 to the entirety of the 30kb MERS-CoV ge-
nome, EIDD-2801 likely causes between 15 (+24 hours
treatment) and 30 (-2 hours treatment) mutations per ge-
nome, 10-20% of which result in amino acid coding changes.
Altogether, our data demonstrates that EIDD-2801-driven
mutagenesis correlates well with the reductions in viral load,
strongly suggestive of an error catastrophe-driven mecha-
nism of action under therapeutic conditions.
DISCUSSION 
In the past 20 years, three novel human coronaviruses have 
emerged (29, 30). The group 2b SARS-like CoV represent an 
existential and future threat to global health as evidenced by 
the emergence of SARS-CoV and SARS-CoV-2. Zoonotic 
SARS-like bat CoV strains can use human angiotensin-con-
verting enzyme 2 (ACE2) receptors, grow well in primary hu-
man airway cells, and vary by as much as 25% in key 
therapeutic and vaccine gene targets (11, 31). Thus, to address 
the current public health emergency of COVID-19 and to max-
imize pandemic preparedness in the future, broad-based vac-
cines and therapeutics, which are active against the higher 
risk RNA virus families prone to emergence, are desperately 
needed. 
Small molecule antivirals can exert their antiviral effect 
through multiple mechanisms including blocking viral entry, 
inhibiting a virally encoded enzyme, blocking virus particle 
formation, or targeting a host factor required for replication 
(32). Multiple direct acting antivirals are currently under 
evaluation in randomized control trials to treat COVID-19 in-
cluding hydroxychloroquine, remdesivir, lopinavir/ri-
tonavir(33-35). Here, we report the broad-spectrum antiviral 
activity of NHC and its orally bioavailable prodrug EIDD-
2801, against SARS-CoV, MERS-CoV, and the current pan-
demic strain SARS-CoV-2 in primary human airway epithelial 
cells. In addition to CoV, NHC is broadly active against mul-
tiple genetically distinct viruses including VEE, influenza A 
and B, Ebola, and Chikungunya viruses (13-16, 19, 21, 24, 36-
38). Here, we show that prophylactic and therapeutic EIDD-
2801 significantly reduced lung viral loads and improved pul-
monary function in mouse models of both SARS- and MERS-
CoV pathogenesis. Although the improvement in both SARS- 
and MERS-CoV outcomes diminished with the delay of treat-
ment initiation time, it is important to note that the kinetics 
of disease in mice are compressed as compared to that in hu-
mans. Whereas SARS- and MERS-CoV lung titers peak on 1-2 
dpi in mice concurrent with the onset of clinical signs and 
notable damage to the lung epithelium, in humans this oc-
curs 7-10 days after the onset of symptoms (19, 28, 39, 40). 
Thus, in mice, the window within which to treat emerging 
CoV infection prior to peak replication is compressed (e.g., 
24-48 hours). As with oseltamivir treatment for influenza
which fails to provide a protective effect if administered >5
days after the onset of symptoms, the window in which to
treat COVID-19 patients prior to peak virus replication is
likely during the first week of symptoms when pharyngeal
shedding is at its highest(41, 42). However, virus replication
and shedding may continue for several weeks in the most se-
vere COVID-19 patients(34). Thus, early intervention with an
antiviral like EIDD-2801 is likely to provide the most clinical
benefit although there may opportunities in severe patients
where the duration of virus replication may be extended. Our
current study is clearly limited by the lack of in vivo efficacy
testing with SARS-CoV-2. Currently, robust mouse models
that recapitulate the SARS-CoV-2 pathogenesis observed in
humans do not yet exist due to a noted virus spike glycopro-
tein and mouse ACE2 receptor incompatibility complicating
the evaluation of medical countermeasures(43, 44). In addi-
tion, SARS-CoV and MERS-CoV, SARS-CoV-2 disease severity
increases with increasing age. Our studies are limited by the
lack of drug efficacy testing in CoV aged mouse models that
recapitulate the age-related increase in pathogenesis ob-
served in humans(45). The data provided in this manuscript 
suggest that EIDD-2801 should be quickly evaluated in pri-
mate models of human disease, using immediate models for 
MERS-CoV and SARS-CoV pathogenesis or newly described 
cynomolgus and rhesus macaque models for SARS-CoV-2 (46-
49). 
For VEE and influenza, NHC/EIDD-2801 exerts its antivi-
ral activity on the RNA-dependent RNA polymerase leading 
to error catastrophe by inducing an error rate of replication 
that surpasses the error threshold allowed to sustain a virus 
population (14, 15). This process occurs when NHC is incor-
porated during RNA synthesis then subsequently misread 
thus increasing mutation rates. Therefore, for CoV, the NHC 
MOA would appear less likely to be affected by the RNA 
proofreading activity encoded by the nsp14 exonuclease func-
tion that otherwise limits misincorperation (50). Here, we 
present data using Primer ID NGS to quantitate the fre-
quency and identity of the mutational spectra in the MERS-
CoV genome in both drug-treated primary human airway 
cells and in mice at single genome resolution. As CoV are pos-
itive sense RNA viruses that replicate through a negative 
sense RNA intermediate, NHC incorporation as a C or a U 
can occur in both polarities of RNA. We found increased nu-
cleotide transitions (A to G, G to A, C to U, U to C) consistent 
with those reported after influenza and VEE infections (14, 
15). Under identical conditions, RDV did not alter the muta-
tion rate in MERS-CoV genomic RNA, supporting its reported 
mechanism of action as a chain terminator of viral RNA syn-
thesis (26). In primary human lung cell cultures and mice in-
fected with MERS-CoV, the NHC mutation rates inversely 
correlated with a reduction in infectious virus. In addition, 
we found a positive correlation between increased mutation 
rates and the frequency of nonsynonymous mutations and 
the degree of therapeutic efficacy in mice. To explore the po-
tential off-target effect in host mRNA which may contribute 
to drug toxicity, we also examined the impact of NHC treat-
ment on ISG15 transcripts, a gene highly induced following 
MERS-CoV infection. Although ISG15 transcripts are present 
in great abundance, an accumulation of mutations was not 
observed in ISG15 in this model even at 500 mg/kg dosing. 
These data also support previous studies using RNAseq to 
demonstrate that the model coronavirus MHV displayed in-
creased mutation frequencies following NHC treatment in 
vitro (16). With regard to nucleic acid specificity, ribonucleo-
tides are efficiently removed from eukaryotic cell DNA; there-
fore, treating a viral infection with a mutagenic 
ribonucleoside analog should show a selectivity for incorpo-
ration into the viral genome and not be efficient at being in-
corporated into and inducing mutations into host cell DNA 
(51). All together, these data strongly support the notion that 
EIDD-2801 and its active nucleoside analog NHC exert their 
antiviral effect through the induction of error catastrophe in 
the targeted virus. While our data suggest that the MERS-CoV 
nsp14 proofreading activity appeared ineffective against NHC 
in vitro and EIDD-2801 in vivo, future studies should investi-
gate the antiviral activity of NHC in the presence or absence 
of the nsp14 proofreading activity, as loss of this activity in-
creased the sensitivity of MHV and SARS-CoV replication to 
RDV treatment (50). 
Together, our data support the continued development of 
EIDD-2801 as a potent broad spectrum antiviral that could 
be useful in treating contemporary, newly emerged and 
emerging coronavirus infections of the future. 
MATERIALS AND METHODS 
Study Design 
The primary goal of this study was to determine the antiviral 
activity of the nucleoside analog NHC (EIDD-1931) against 
multiple emerging CoV in vitro and antiviral efficacy of its 
prodrug, EIDD-2801, in mouse models of CoV pathogenesis. 
Coupling cell lines and primary HAE cell cultures, we evalu-
ated the antiviral activity of NHC against the three most re-
cently emerged human CoV: SARS-CoV, MERS-CoV, and 
SARS-CoV-2. For both SARS-CoV and MERS-CoV, the data 
presented for HAE studies are representative of those from 2-
3 separate human donors. For SARS-CoV-2, the HAE were 
from a single human donor. We evaluated drug cytotoxicity 
in both Calu-3 2B4 and HAE cell cultures. Calu-3 and the 
SARS-CoV and MERS-CoV HAE studies were performed in 
biological triplicate. HAE studies with SARS-CoV-2 and the 
SARS- and MERS-like bat CoV were performed with two wells 
per condition. Drug effects were measured relative to vehicle 
controls in vitro and comparisons in vivo were performed to 
vehicle controls. We also aimed to determine the antiviral ef-
ficacy of EIDD-2801 in mouse models of CoV pathogenesis. 
These studies were intended to provide the preclinical data 
to justify nonhuman primate studies and human clinical tri-
als. Mice were age- and sex-matched and randomly assigned 
into groups before infection and treatment. Pathology was 
scored blinded by a board-certified veterinary pathologist. 
Primary data for all studies are provided in data file S1. 
Ethics regulation of laboratory animals 
Efficacy studies were performed in animal biosafety level 3 
facilities at UNC Chapel Hill. All work was conducted under 
protocols approved by the Institutional Animal Care and Use 
Committee at UNC Chapel Hill (IACUC protocol #16-284) ac-
cording to guidelines set by the Association for the Assess-
ment and Accreditation of Laboratory Animal Care and the 
U.S. Department of Agriculture. 
Compounds 
The parental compound β−D−N4-hydroxycytidine (NHC, all
in vitro studies) and its prodrug EIDD-2801 (all in vivo stud-
ies) was supplied by Emory University Institute for Drug 
Discovery (EIDD). NHC was supplied as a 10 mM stock in 
DMSO and EIDD-2801 as a solid and solubilized in vehicle 
containing 10% PEG400, 2.5% Cremophor RH40 in water 
(10/2.5/87.5%, all v/v) prior to use. RDV was solubilized in 
100% DMSO and provided by Gilead Sciences, Inc as previ-
ously described (18, 19). 
Cell cultures 
At UNC, the human lung epithelial cell line Calu-3 2B4 cells 
was maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco), 20% fetal bovine serum (Hyclone) and 1x an-
tibiotic/antimycotic (Gibco). At Vanderbilt University Medi-
cal Center (VUMC), Calu-3 2B4 were propagated in DMEM 
supplemented with 20% FBS (Gibco), 100 U/ml penicillin and 
streptomycin (Gibco), and 0.25 μM amphotericin B (Corn-
ing). At VUMC, VeroE6 cells were cultured in DMEM supple-
mented with 10% FBS (Gibco), 100 U/ml penicillin and 
streptomycin (Gibco), and 0.25 μM amphotericin B (Corn-
ing). At UNC, VeroE6 cells were cultured in DMEM supple-
mented with 10% Fetal Clone II (Hyclone) and 1x 
antibiotic/antimycotic (Gibco). Murine delayed brain tumor 
(DBT) cells were maintained in DMEM supplemented with 
10% FBS (Gibco), 100 U/ml penicillin and streptomycin 
(Gibco), and 0.25 μM amphotericin B (Corning). Primary hu-
man airway epithelial (HAE) cell cultures were obtained from 
the Tissue Procurement and Cell Culture Core Laboratory in 
the Marsico Lung Institute/Cystic Fibrosis Research Center 
at UNC and are described more thoroughly below (52). 
Virus strains 
Except for SARS-CoV-2, all viruses used for these studies were 
derived from infectious clones and isolated as previously de-
scribed (53). SARS-CoV-2 clinical isolate was obtained at 
VUMC and UNC from the CDC (2019-nCoV/USA-WA1/2020 
strain, GenBank accession no. MN985325.1) and passaged 
twice in Vero E6 cells at each respective institution to create 
a passage 5 working stock (54). Virus strains for in vitro ex-
periments include SARS-CoV expressing the green fluores-
cent protein (GFP) in place of open reading frames 7a/b 
(ORF7a/b, SARS-GFP)(53), bat-spike receptor binding do-
main (Bat-SRBD)(22), a chimeric CoV strain derived from the 
HKU3 SARS-like bat coronavirus genomic sequence that has 
the wild type (Urbani SARS-CoV strain) RBD in the HKU3 
spike gene to allow for virus replication in non-human pri-
mate cell lines and HAE cultures, SHC014 SARS-like bat coro-
navirus (11), MERS-CoV expressing nanoluciferase in the 
place of ORF3 (MERS-nLUC)(19), and MERS-CoV expressing 
the red fluorescent protein gene in the place of ORF 5 (RFP, 
MERS-RFP)(55). The virus stock utilized for MERS-CoV in 
vivo studies was derived from a plaque-purified isolate of the 
mouse-adapted MERS-CoV p35C4 strain (56). The virus stock 
utilized for SARS-CoV in vivo studies was derived from the 
infectious clone of the mouse-adapted SARS-CoV MA15 
(MA15) strain (57). All work with MHV was performed using 
the recombinant WT strain MHV-A59 (GenBank accession 
no. AY910861)(58). 
In vitro antiviral activity experiments 
MERS-CoV nLUC in Calu-3: At 48 hours prior to infection, 
Calu-3 2B4 cells were plated in a 96-well black-walled clear 
bottom plate at 5x104 cells/well. A 10 mM stock of NHC was 
serially diluted in 100% DMSO in 3-fold increments to obtain 
a ten-point dilution series. MERS-nLUC was diluted in 
DMEM supplemented with 10% FBS, and 1% Antibiotic-Anti-
mycotic to achieve a multiplicity of infection (MOI) of 0.08. 
Cells were infected and concurrently treated with NHC in 
triplicate per drug dilution for 1hr, after which viral inoculum 
was aspirated, cultures were rinsed once and fresh medium 
containing drug or vehicle was added. At 48 hours post infec-
tion, nanoluciferase expression as a surrogate for virus repli-
cation was quantitated on a Spectramax plate reader 
(Molecular Devices) according to the manufacturer’s instruc-
tions (Promega, NanoGlo). For the 100% inhibition control, 
diluted MERS-nLUC was exposed to short-wave UV light 
(UVP, LLC) for 6 min to inhibit the ability of the virus to rep-
licate. For the 0% inhibition control, cells were infected in the 
presence of vehicle only. DMSO was kept constant in all con-
ditions at 0.05%. Values from triplicate wells per condition 
were averaged and compared to controls to generate a per-
cent inhibition value for each drug dilution. The IC50 value 
was defined as the concentration at which there was a 50% 
decrease in luciferase expression. Data were analyzed using 
GraphPad Prism 8.0. The IC50 values were calculated by non-
linear regression analysis using the dose-response (variable 
slope) equation (four parameter logistic equation): Y = Bot-
tom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). To 
measure cell viability to determine if there was any NHC-
induced cytotoxicity, Calu-3 2B4 cells were plated and treated 
with NHC only as described above. Cells were exposed to the 
same ten-point dilution series created for the in vitro efficacy 
studies. As above, 0.05% DMSO-treated cells served as the 0% 
cytotoxicity control. Wells without cells served as the 100% 
cytotoxic positive control. After 48 hours, cell viability was 
measured on a Spectramax (Molecular Devices) via Cell-Titer 
Glo Assay (Promega) according to the manufacturer’s proto-
col. Similar data were obtained in three independent experi-
ments. 
SARS-CoV-2 in Calu-3: Calu-3 2B4 cells were adsorbed 
with MOI 0.1 PFU/cell of SARS-CoV-2 (2019-nCoV/USA-
WA1/2020 strain) at 37°C. Plates were manually rocked every 
10 min to redistribute the inoculum. After 30 min, virus inoc-
ulum was removed, cells were washed with Phosphate buff-
ered saline (PBS) once to remove unbound virus, medium 
containing NHC or vehicle control (DMSO) was added back 
onto the cells, and cells were incubated for 72 hours at 37°C. 
SARS-CoV-2 in Vero E6: Vero E6 cells were plated at 
20,000 cells/well in a 96-well plate. 24hr later, medium 
containing a dose response of NHC was added concurrent 
with SARS-CoV-2 (2019-nCoV/USA-WA1/2020 strain) at an 
MOI of 0.05. 48 hours post infection, cell viability was meas-
ured by CellTiter Glo assay. 
SARS-CoV, MERS-CoV, and SARS-CoV-2 in HAE: Human 
tracheobronchial epithelial cells provided by Dr. Scott Ran-
dell were obtained from airway specimens resected from pa-
tients undergoing surgery under University of North Carolina 
Institutional Review Board-approved protocols (#03-1396) by 
the Cystic Fibrosis Center Tissue Culture Core. Primary cells 
were expanded to generate passage 1 cells and passage 2 cells 
were plated at a density of 250,000 cells per well on 
Transwell-COL (12mm diameter) supports (Corning). Human 
airway epithelium cultures (HAE) were generated by provi-
sion of an air-liquid interface for 6 to 8 weeks to form well-
differentiated, polarized cultures that resembled in vivo pseu-
dostratified mucociliary epithelium (59).· At 48 hours prior 
to infection the apical surface of the culture was washed with 
500 μL PBS for 1.5 hours at 37°C and the cultures moved into
fresh air liquid interface (ALI) media. Immediately prior to 
infection, apical surfaces were washed twice to remove accu-
mulated mucus with 500 μL of PBS with each wash lasting
30 min at 37°C and HAE cultures were moved into ALI media 
containing various concentrations of NHC ranging from 10 
μM to 0.0016 μM as indicated for each experiment (final %
DMSO < 0.05%). Upon removing the second PBS wash, 200 
μL of viral inoculum (SARS-GFP, MERS-RFP or 2019-
nCoV/USA-WA1/2020 strain) at an MOI of 0.5 was added to 
the apical surface and HAE cultures were incubated for 2 
hours at 37°C. Viral inoculum was then removed, and the ap-
ical surface of the cultures were washed three times with 
500μL PBS and then incubated at 37°C until 48 hours post
infection (hpi). For all HAE cultures, infectious virus pro-
duced was collected by washing the apical surface of the cul-
ture with 100 μL PBS. Apical washes were stored at -80°C
until analysis and titered by plaque assay as previously de-
scribed (19). 
qRT-PCR approach to assess cytotoxicity 
Total RNA was isolated using the Zymo Direct-zol RNA Min-
iPrep Kit (Zymo Research Corp.) according to the manufac-
turer’s directions. Cells were treated with 1μM staurosporine
(Sigma-Aldrich) as a positive control. First-strand cDNA was 
generated using Superscript III reverse transcriptase (Life 
Technologies). For quantification of cellular markers of tox-
icity/apoptosis, real-time PCR was performed using commer-
cially validated TaqMan-based primer-probe sets (table S1) 
and TaqMan Universal PCR Mix (Life Technologies). Results 
were then normalized as described above. 
MERS-CoV genomic RNA qRT-PCR 
Mouse lungs were stored in RNAlater (ThermoFisher) at -
80°C until processed via homogenization in TRIzol (Invitro-
gen). Total RNA was isolated using Direct-zol RNA MiniPrep 
kit (Zymo Research). Previously published TaqMan primers 
were synthesized by Integrated DNA Technologies (IDT) to 
quantify MERS genomic RNA (targeting orf1a: Forward: 5′-
GCACATCTGTGGTTCTCCTCTCT-3′, Probe (6-
FAM/ZEN/IBFQ): 5′- TGCTCCAACAGTTACAC-3′, Reverse:
5′-AAGCCCAGGCCCTACTATTAGC)(60). qRT-PCR was per-
formed using 100ng total RNA compared to an RNA standard 
curve using TaqMan Fast Virus 1-Step Master Mix (Ther-
moFisher) on a Quant Studio 3 (Applied Biosystems). 
Quantification of SARS-CoV-2 viral RNA genome copy 
number by qRT-PCR 
Cell supernatants were harvested in TRIzol LS reagent (Invi-
trogen), and RNA was purified following phase separation by 
chloroform as recommended by the manufacturer. The RNA 
in the aqueous phase was collected and further purified using 
PureLink RNA Mini Kits (Invitrogen) according to the man-
ufacturer’s protocol. Viral RNA was quantified using one-step 
quantitative reverse transcription PCR (qRT-PCR) on a 
StepOnePlus Real-Time PCR system (Applied Biosystems) by 
TaqMan Fast Virus 1-Step Master Mix chemistry (Applied Bi-
osystems). SARS-CoV-2 N gene RNA was amplified using for-
ward (5′-GACCCCAAAATCAGCGAAAT) and reverse (5′-
TCTGGTTACTGCCAGTTGAATCTG) primers and probe (5′-
FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1) designed by 
the United States Centers for Disease Control and Prevention 
(oligonucleotides produced by IDT, cat# 10006606). Copy 
numbers were interpolated from a standard curve produced 
with dilutions of N gene RNA. Briefly, SARS-CoV-2-N positive 
control plasmid DNA (IDT, cat# 10006625) was amplified us-
ing forward (5′-
TAATACGACTCACTATAGGGATGTCTGATAATGGACCCCA) 
and reverse (5′- TTAGGCCTGAGTTGAGTCAG) primers, re-
sulting in a 1280 nucleotide fragment containing a T7 pro-
moter. The PCR product was purified by column (Promega) 
and in vitro transcribed using the mMESSAGE mMACHINE 
T7 Transcription Kit (Invitrogen) according to the manufac-
turer’s protocol. Transcribed RNA was purified using RNeasy 
mini kit (Qiagen) according to the manufacturer’s protocol, 
and serial 10-fold dilutions were quantified as described 
above. 
Primer ID and deep sequencing 
Primer ID NGS is designed to specifically identify and remove 
RT-PCR mutations, while facilitating highly accurate se-
quence determination of single RNA molecules, because each 
cDNA is created with a barcoded degenerate primer (N10, 410 
combinations) from which Illumina indexed libraries are 
made. We used a multiplexed Primer ID library prep ap-
proach and MiSeq sequencing to investigate the presence of 
mutations in the viral genomes and murine mRNA. We de-
signed cDNA primers targeting multiple regions on the viral 
genome and murine mRNA, each with a block of random 
nucleotides (11 bp long) as the Primer ID (25, 61) (table S2). 
Viral RNA was extracted using QIAamp viral RNA kit. A pre-
amplification titration of templates was performed to esti-
mate the amount of template to use. We used SuperScript III 
to make cDNA with multiplexed cDNA primers based on the 
regions to be sequenced. We used 41R_PID11 for the pilot se-
quencing and titration determination. For the MERS-CoV se-
quencing, we multiplexed nsp10_PID11, nsp12_PID11 and 
nsp14_PID11 for the cDNA reaction; for the murine mRNA 
sequencing, we used mixed primers of nsp10_PID11, 
ifit3_PID11, isg15_PID11. After bead purification, we ampli-
fied the cDNA with a mixture of forward primers (based on 
the described schemes) and a universal reverse primer, fol-
lowed by another round of PCR to incorporate Illumina se-
quencing adaptors and barcodes in the amplicons. After gel-
purification and quantification, we pooled 24 libraries for 
MiSeq 300 base paired-end sequencing. The TCS pipeline ver-
sion 1.38 (https://github.com/SwanstromLab/PID) was used 
to process the Primer ID sequencing data and construct tem-
plate consensus sequences (TCSs) to represent each individ-
ual input templates, and the sequences of each region in the 
pool was de-multiplexed. The RUBY package viral_seq ver-
sion 1.0.6 (https://rubygems.org/gems/viral_seq) was used to 
calculate the mutation rate at each position. NCBI SRA Ac-
cession numbers for sequence data are as follows: 
PRJNA613261 (Fig. 5) and PRJNA613454 (Fig. 7). 
In vivo experiments 
We performed 4 mouse studies to evaluate the in vivo efficacy 
of the NHC prodrug (EIDD-2801). First, we performed 
prophylactic dose escalation studies for both SARS- and 
MERS-CoV to determine the most efficacious dose of EIDD-
2801 per virus. For SARS-CoV, in cohorts of equivalent num-
bers of male and female 20-29 week old SPF C57BL/6J (Stock 
000664 Jackson Labs) mice (n = 10/dose group), we admin-
istered vehicle (10% PEG, 2.5% Cremophor RH40 in water) or 
50, 150 or 500 mg/kg EIDD-2801 by oral gavage 2 hours prior 
to intranasal infection with 1E+04 PFU mouse-adapted 
SARS-CoV strain MA15 in 50μl. Mice were anaesthetized with
a mixture of ketamine/xylazine prior to intranasal infection. 
Vehicle or drug was administered every 12hr for the remain-
der of the study. Body weight and pulmonary function by 
whole body plethysmography were measured daily. On 5 dpi, 
animals were sacrificed by isoflurane overdose, lungs were 
scored for lung hemorrhage, and the inferior right lobe was 
frozen at −80°C for viral titration via plaque assay. Briefly, 
500,000 Vero E6 cells/well were seeded in 6-well plates. The 
following day, medium was removed and serial dilutions of 
clarified lung homogenate were added per plate (10−1 to 10−6 
dilutions) and incubated at 37°C for 1hr after which wells 
were overlaid with 1X DMEM, 5% Fetal Clone 2 serum, 1X 
antibiotic/antimycotic, 0.8% agarose. Two days after, plaques 
were enumerated to generate a plaque/ml value. Lung 
hemorrhage is a gross pathological phenotype readily ob-
served by the naked eye driven by the degree of virus replica-
tion where the coloration of the lung changes from pink to 
dark red (62, 63). The large left lobe was placed in 10% buff-
ered formalin and stored at 4°C for 1-3 weeks until histologi-
cal sectioning and analysis. For MERS-CoV, the prophylactic 
dose escalation studies we performed similarly as done for 
SARS-CoV with our recently developed a mouse model for 
MERS-CoV, which has a humanized DPP4 receptor (hDPP4) 
(28). We performed all in vivo studies with EIDD-2801 in 
equivalent numbers of 10-14 week old female and male 
C57BL/6J hDPP4 mice. Second, we intranasally infected mice 
with 5E+04 PFU mouse-adapted MERS-CoV strain M35C4 in 
50μl. Third, to titer lungs by plaque assay, Vero CCL81 cells
were used and plaques were enumerated 3 dpi. 
To determine the time at which therapeutic administra-
tion of EIDD-2801 would fail to improve outcomes with 
SARS-CoV or MERS-CoV infection, we performed therapeutic 
efficacy studies in mice where we initiated treatment 2 hours 
prior to infection or 12, 24 or 48 hours after infection. As 500 
mg/kg provided the most complete protection from disease 
in prophylactic SARS-CoV studies, this dose was used for both 
therapeutic efficacy studies. Vehicle or EIDD-2801 was given 
via oral gavage twice daily following initiation of treatment. 
For both SARS-CoV and MERS-CoV, the infectious dose for 
the therapeutic studies and the mouse strains were the same 
as that used in the prophylactic studies. The numbers of mice 
per group for the SARS-CoV studies were as follows: Vehicle 
(n = 10), -2 hours (n = 10), +12 hours (n = 10), +24 hours (n = 
10), +48 hours (n = 10). The numbers of mice per group for 
the MERS-CoV therapeutic studies were as follows: Vehicle 
(n = 9), -2 hours (n = 9), +12 hours (n = 9), +24 hours (n = 7), 
+48 hours (n = 10). As described above, each day mouse body
weight and pulmonary function were quantitated. On 5 dpi
for SARS-CoV and 6 dpi for MERS-CoV, animals were hu-
manely sacrificed and tissues were harvested and analyzed as
described above. In addition, for the MERS-CoV study, lung
tissue was harvested and stored in RNAlater (Thermo Fisher)
at -80°C and then thawed, homogenized in Trizol reagent
(Invitrogen) and total RNA was isolated using a Direct-zol
RNA MiniPrep kit (Zymo Research). This total RNA was then
used for Primer ID and qRT-PCR.
Whole body plethysmography 
Pulmonary function was monitored once daily via whole-
body plethysmography (Buxco Respiratory Solutions, DSI 
Inc.). Mice intended for this analysis were randomly chosen 
prior to the initiation of the study. Briefly, after a 30-min ac-
climation time in the plethysmograph, data for 11 parameters 
was recorded every 2 s for 5 min. 
Acute lung injury histological assessment tools 
Two different and complementary quantitative histologic 
tools were used to determine if antiviral treatments 
diminished the histopathologic features associated with lung 
injury. Both analyses and scoring were performed by a Board 
Certified Veterinary Pathologist who was blinded to the treat-
ment groups. 
American Thoracic Society lung injury scoring tool. In or-
der to help quantitate histological features of ALI observed 
in mouse models and increase their translation to the human 
condition, we used the ATS scoring tool (63). In a blinded 
manner, we chose three random diseased fields of lung tissue 
at high power (60 ×), which were scored for the following: 
(A) neutrophils in the alveolar space (none = 0, 1–5 cells = 1,
> 5 cells = 2), (B) neutrophils in the interstitial space/ septae
(none = 0, 1–5 cells = 1, > 5 cells = 2), (C) hyaline membranes
(none = 0, one membrane = 1, > 1 membrane = 2), (D) Pro-
teinaceous debris in air spaces (none = 0, one instance = 1, >
1 instance = 2), (E) alveolar septal thickening (< 2× mock
thickness = 0, 2–4× mock thickness = 1, > 4× mock thickness
= 2). To obtain a lung injury score per field, the scores for A–
E were then put into the following formula, which contains
multipliers that assign varying levels of importance for each
phenotype of the disease state.: score = [(20x A) + (14 x B) +
(7 x C) + (7 x D) + (2 x E)]/100. The scores for the three fields
per mouse were averaged to obtain a final score ranging from
0 to and including 1.
Diffuse Alveolar Damage (DAD) tool. The second histolog-
ical tool to quantitate lung injury was reported by Schmidt et 
al.(64). DAD is the pathological hallmark of ALI (63, 64). 
Three random diseased fields of lung tissue were scored at 
high power (60 ×) for the following in a blinded manner: 1 = 
absence of cellular sloughing and necrosis, 2 = Uncommon 
solitary cell sloughing and necrosis (1–2 foci/field), 3 = mul-
tifocal (3 + foci) cellular sloughing and necrosis with uncom-
mon septal wall hyalinization, or 4 = multifocal (>75% of 
field) cellular sloughing and necrosis with common and/or 
prominent hyaline membranes. The scores for the three fields 
per mouse were averaged to get a final DAD score per mouse. 
nsp12 phylogenetic analysis and conservation modeling 
Coronavirus RdRp (nsp12) protein sequence alignments and 
phylogenetic trees were generated using Geneious Tree 
Builder in Geneious Prime (version 2020.0.5) and visualized 
using Evolview (https://www.evolgenius.info/evolview/). 
Protein similarity scores were calculated using Blosom62 ma-
trix. The accession numbers used were: PDCoV (KR265858), 
AIBV (NC_001451), HCoV-229E (JX503060), PEDV 
(NC_003436), MHV (AY700211), HCoV-HKU1 (DQ415904), 
HCoV-NL63 (JX504050), HCOV-OC43 (AY903460), HKU5-1 
(NC_009020), MERS-CoV (JX869059), HKU9-4 (EF065516), 
2019-nCoV (MN996528), HKU3-1 (DQ022305), SHC014 
(KC881005), WIV1 (KF367457), SARS-CoV (AY278741). Amino 
acid conservation scores of coronavirus RdRp were generated 
using ConSurf Server (https://consurf.tau.ac.il/) using the 
protein alignment described above and visualized on the 
SARS-CoV RdRp structure (PDB: 6NUR) in PyMol (version 
1.8.6.0)(20, 65). 
Statistical analysis 
All statistical data analyses were performed in Graphpad 
Prism 8. Statistical significance for each endpoint was deter-
mined with specific statistical tests. In general, for metrics 
with multiple treatment groups with longitudinal data (e.g., 
mouse weight loss or pulmonary function over time), two-
way ANOVA was performed with the suggested multiple com-
parison test as advised by Prism. For comparative data with 
for a single timepoint (e.g., lung titer) Kruskal-Wallis or one-
way ANOVA was performed with the suggested multiple com-
parison test. For each test, a p-value <0.05 was considered 
significant. Specific tests are noted in each figure legend. 
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Fig. 1. NHC potently inhibits MERS-CoV and newly emerging SARS-CoV-2 replication. (A) Percent 
inhibition of MERS-CoV replication and NHC cytotoxicity in Calu-3 cells. Calu-3 cells were infected in 
triplicate with MERS-CoV nanoluciferase (nLUC) at a multiplicity of infection (MOI) of 0.08 in the 
presence of a range of drug for 48 hours, after which replication was measured through quantitation 
of MERS-CoV–expressed nLUC. Cytotoxicity was measured in similarly treated but uninfected 
cultures via Cell-Titer-Glo assay. Data are combined from 3 independent experiments. (B) NHC 
antiviral activity and cytotoxicity in Vero E6 cells infected with SARS-CoV-2. Vero E6 cells were 
infected in duplicate with SARS-CoV-2 clinical isolate 2019-nCoV/USA-WA1/2020 virus at an MOI 
of 0.05 in the presence of a range of drug for 48 hours, after which replication was measured through 
quantitation of cell viability by Cell-Titer-Glo assay. Cytotoxicity was measured as in A. Data are 
combined from 2 independent experiments. (C) SARS-CoV-2 titer reduction (left) and percent 
inhibition (right) in Calu-3 cells. Cells were infected with at an MOI of 0.1 for 30 min, washed and 
exposed to a dose response of NHC in triplicate per condition. 72 hours post infection, virus 
production was measured by plaque assay. (D) SARS-CoV-2 genomic RNA reduction (left) and 
percent inhibition (right) in Calu-3 cells. Viral RNA was isolated from clarified supernatants from the 
study in panel C. Genome copy numbers were quantitated by qRT-PCR with primer/probes targeting 
the N gene. For A-D, the symbol is at the mean and the error bars represent the standard deviation. 
Fig. 2. NHC is highly active against SARS-CoV-2, MERS-CoV, and SARS-CoV in primary human 
airway epithelial cell cultures. (A) HAE were infected at an MOI of 0.5 with clinical isolate SARS-CoV-
2 for 2 hours in the presence of NHC in duplicate after which virus was removed and cultures were 
washed in incubated in NHC for 48 hours when apical washes were collected for virus titration by 
plaque assay. The line is at the mean. Each symbol represents the titer from a single well. (B) HAE cells 
were infected with MERS-CoV red fluorescent protein (RFP) at an MOI of 0.5 in triplicate and treated 
similarly to A. qRT-PCR for MERS-CoV ORF1 and ORFN mRNA. Total RNA was isolated from cultures 
in C for qRT-PCR analysis. Representative data from three separate experiments with three different 
cell donors are displayed. PFU, plaque-forming units. (C) Studies performed as in A but with SARS-
CoV green fluorescent protein (GFP). Representative data from two separate experiments with two 
different cell donors are displayed. Each symbol represents the data from one HAE culture, the line is 
at the mean and the error bars represent the standard deviation. 
Fig. 3. Remdesivir (RDV) resistance mutations in the highly conserved RNA-dependent RNA polymerase 
increase susceptibility to NHC. (A) Neighbor-joining trees created with representatives from all four CoV 
genogroups showing the genetic similarity of CoV nsp12 (RdRp) and CoV spike glycoprotein, which mediates 
host tropism and entry into cells. Text color of the virus strain label corresponds to virus host species on the left. 
The heatmap adjacent to each neighbor-joining tree depicts percent amino acid identity (% A.A. similarity) 
against mouse hepatitis virus (MHV), SARS-CoV, or MERS-CoV. (B) The variation encompassed in panel A was 
modeled onto the RdRp structure of the SARS-CoV RdRp. (C) Amino acid sequence of CoV in panel A at known 
resistance alleles to antiviral drug RDV. (D) Virus titer reduction assay in DBT cells across a range of NHC with 
recombinant MHV bearing resistance mutations to RDV. Data shown are combined from three independent 
experiments performed with biological duplicates or triplicates per condition. Asterisks indicate statistically 
significant differences by Mann-Whitney test as indicated on the graph. 
Fig. 4. NHC is effective against multiple genetically distinct Bat-CoV. Top: Antiviral efficacy of NHC 
in HAE cells against SARS-like (HKU3, SHC014, group 2b) and MERS-like (HKU5, group 2c) bat-CoV. 
HAE cells were infected at an MOI of 0.5 in the presence of NHC in duplicate. After 48 hours, virus 
produced was titrated via plaque assay. Each data point represents the titer per culture. Bottom: qRT-
PCR for CoV ORF1 and ORFN mRNA in total RNA from cultures in the top panel. Mock, mock-treated. 
Representative data from two separate experiments with two different cell donors are displayed. 
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Fig. 5. NHC antiviral activity is associated with increased viral mutation rates. (A) HAE cultures were infected 
with MERS-CoV red fluorescent protein (RFP) at an MOI of 0.5 in duplicate in the presence of vehicle, RDV, or 
NHC for 48 hours, after which apical washes were collected for virus titration. Data are combined from two 
independent studies. The boxes encompass the 25th to 75th percentile, the line is at the median, while the 
whiskers represent the range. (B) Schematic of Primer ID deep sequencing for single RNA genomes of MERS-
CoV. (C) The total error rate for MERS-CoV RNA isolated from cultures in panel A as determined by Primer ID. 
Error rate values are # mutations per 10,000 bases. Asterisks indicate significant differences as compared to 
untreated group by two-way ANOVA with a Dunnett’s multiple comparison test. (D) Description of potential 
NHC mutational spectra on both positive and negative sense viral RNA. (E) Nucleotide transitions in cDNA 
derived from MERS-CoV genomic RNA. 
Fig. 6. Prophylactic and therapeutic EIDD-2801 reduces SARS-CoV replication and pathogenesis. 
Equivalent numbers of 25-29 week old male and female C57BL/6 mice were administered vehicle (10% PEG, 
2.5% Cremophor RH40 in water) or NHC prodrug EIDD-2801 beginning at -2 hours, +12, +24 or +48 hours 
post infection and every 12 hours thereafter by oral gavage (n = 10/group). Mice were intranasally infected 
with 1E+04 PFU mouse-adapted SARS-CoV MA15 strain. (A) Percent starting weight. Asterisks indicate 
differences from vehicle treated by two-way ANOVA with Tukey’s multiple comparison test. (B) Lung 
hemorrhage in mice from panel A scored on a scale of 0-4 where 0 is a normal pink healthy lung and 4 is a 
diffusely discolored dark red lung. (C) Virus lung titer in mice from panel A as determined by plaque assay. 
Asterisks in both panel B and C indicate differences from vehicle by one-way ANOVA with a Dunnett’s 
multiple comparison test. (D) Pulmonary function by whole body plethysmography was performed daily on 
five animals per group. Asterisks indicate differences from vehicle by two-way ANOVA with a Dunnett’s 
multiple comparison test. (E) The histological features of acute lung injury (ALI) were blindly scored using 
the American Thoracic Society Lung Injury Scoring system and a Diffuse Alveolar Damage Scoring System. 
Three randomly chosen high power (60X) fields of diseased lung were assessed per mouse. The numbers of 
mice scored per group: Vehicle N = 7, -2 hours N = 9, +12 hours N = 9, +24 hours N = 10, +48 hours N = 9. 
Asterisks indicate statistical significance compared to vehicle by Kruskal-Wallis with a Dunn’s multiple 
comparison test. For all panels, the boxes encompass the 25th to 75th percentile, the line is at the median, 
while the whiskers represent the range. *, -2 hours and +12 hours compared to vehicle; **, +24 hours 
compared to vehicle; ***, +48 hours compared to vehicle. 
Fig. 7. Prophylactic and therapeutic EIDD-2801 reduces MERS-CoV replication and pathogenesis coincident 
with increased viral mutation rates. Equivalent numbers of 10-14 week old male and female C57BL/6 hDPP4 mice 
were administered vehicle (10% PEG, 2.5% Cremophor RH40 in water) or NHC prodrug EIDD-2801 beginning at -2 
hours, +12, +24 or +48 hours post infection and every 12 hours thereafter by oral gavage (n = 10/group). Mice were 
intranasally infected with 5E+04 PFU mouse-adapted MERS-CoV M35C4 strain. (A) Percent starting weight. 
Asterisks indicate differences between -2 hours and +12 hours group from vehicle by two-way ANOVA with Tukey’s 
multiple comparison test. (B) Lung hemorrhage in mice from panel A scored on a scale of 0-4 where 0 is a normal 
pink healthy lung and 4 is a diffusely discolored dark red lung. (C) Virus lung titer in mice from panel A as determined 
by plaque assay. Asterisks in both panel B and C indicate differences from vehicle by Kruskal-Wallis with Dunn’s 
multiple comparison test. (D) MERS-CoV genomic RNA in lung tissue by qRT-PCR. Asterisks indicate differences by 
one-way ANOVA with a Dunnett’s multiple comparison test. (E) Pulmonary function by whole body plethysmography 
was performed daily on four animals per group. Asterisks indicate differences from vehicle by two-way ANOVA with 
Tukey’s multiple comparison test. (F) Workflow to measure mutation rate in MERS-CoV RNA and host transcript 
ISG15 by Primer ID in mouse lung tissue. (G) Number of template consensus sequences (TCS) for MERS-CoV nsp10 
and ISG15. (H) Total error rate in MERS-CoV nsp10 and ISG15. (I) The cytosine to uridine transition rate in MERS-
CoV nsp10 and ISG15. In panels G-I, asterisks indicate differences from vehicle by two-way ANOVA with Tukey’s 
multiple comparison test. (J) Codon change frequency in MERS-CoV nsp10. Asterisks indicate differences from 
vehicle by Kruskal-Wallis with Dunn’s multiple comparison test. For all panels, the boxes encompass the 25th to 75th 
percentile, the line is at the median, while the whiskers represent the range. 
